Defining the Public Health Risks of Counterfeit Pharmaceuticals
Product Format: Audio Conference
Presenter(s): Douglas C. Moyer, PhD, CPP
Pharmaceutical companies get into risk with the counterfeiting problems as it negatively impacts their
brand reputation and diminishes returns on new drug development.
This session ‘Defining the Public Health Risks of Counterfeit Pharmaceuticals’ on Tue, Jun 03, 2014
by Douglas C. Moyer, PhD, CPP will provide participants a full understanding of counterfeit
pharmaceuticals and they’ll also be able to understand:
The diversity and complexity of counterfeiting in general and pharmaceuticals in particular
How counterfeit pharmaceuticals pose risks at both the patient and population levels
The various types of patient conditions, counterfeit types, and patient reactions will be
The various risks at population levels will be presented including the potential for detection
and much more…
For more information, go to http://www.audioeducator.com/pharma-biotech/public-health-risks-
Special Offer: Use code SAVE10 to get 10% discount.
Can’t attend? Request a replay of the audio session or DVD recording